High demand expected for new daily weight loss pill
Pharmaceutical company Eli Lilly said it expects substantial demand when the new pill is launched.
Lilly said it will seek approval by international regulators as it published the results of a large study into orforglipron.
The new pill is a GLP-1 agonist, a type of medication which helps lower blood sugar levels, slows the digestion of food and can reduce appetite.
The manufacturer also makes Mounjaro, dubbed the King Kong of weight loss jabs.
Weight loss jabs have been hailed as transformative by health leaders.
But injections come with additional work for over-stretched health services so tablet forms of medication, which are expected to be cheaper and easier to use, may offer a new hope for the millions of people looking to lose weight.
The new study data on orforglipron showed that people taking the drug lost an average of 12.3 kilograms while taking the drug for 72 weeks compared with those not taking the drug.
Three in five (60%) of people taking the highest dose of orforglipron lost at least 10% of their body weight, while 40% lost at least 15% of their body weight, according to the study, which is to be presented to the European Association for the Study of Diabetes (EASD) Annual Meeting 2025.
A once-a-day pill to treat obesity could be a game-changer. Today we announced positive results of a late-stage clinical trial studying a once-daily oral medicine for obesity. Read more: https://t.co/nsf4ACtbVD pic.twitter.com/MdD07UYfcL
— Eli Lilly and Company (@EliLillyandCo) August 7, 2025
In addition to weight loss the people in the study also showed other health benefits, including improvements in cholesterol, blood pressure and heart disease risk.
Experts highlighted how the tablet did not appear to yield the same benefits as some weight loss jabs, but said they will be more 'tolerable' for many patients.
Lilly said the safety profile of the tablet is similar to other GLP-1 drugs, with gastrointestinal issues the most commonly reported side effect.
The pill was assessed in a study of 3,127 adults who were obese or overweight, with a weight-related medical problem and without diabetes.
'With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments,' said Lilly's Kenneth Custer.
'With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need.'
Dr Simon Cork, senior lecturer in physiology at Anglia Ruskin University, said: 'These preliminary results on the effectiveness of orforglipron in promoting clinically significant weight loss are a positive step forward in the development of this class of drugs.
'It should be noted that their effects on weight loss are not as profound as that seen in injectable GLP-1 receptor agonists, such as Wegovy, with a lower percentage weight loss and fewer people achieving 10% weight loss at the highest dose.
'Nevertheless, that this medication is an oral form, rather than injectable, will likely be seen as more tolerable for many patients.
'The manufacturing costs are also anticipated to be significantly lower than injectable drugs, meaning these medications may be more equitable in their availability.
'It should be noted that these are preliminary, non-peer reviewed results and we will need to see the full trial methodology and data before a more comprehensive analysis can be undertaken.'
It comes as a separate study highlighted the potential other benefits of using GLP-1s, also known as glucagon-like peptide 1 receptor-agonists.
They were initially developed as a treatment for people with type 2 diabetes and are now widely used to treat obesity and help people lose weight.
The separate paper, from McGill University and the Lady Davis Institute for Medical Research at the Jewish General Hospital in Canada, examined the benefits of these drugs beyond weight loss by looking at trials which had assessed the drugs in other areas of medicine.
Writing in the journal eClinicalMedicine, experts said GLP-1s may also play a role in improving liver disease; sleep apnoea; arthritis of the knee; polycystic ovary syndrome; Parkinson's disease; Alzheimer's disease and substance misuse.
But they also highlighted potential safety issues linked to the drugs including potential issues with the pancreas and gall bladder.
'The therapeutic landscape for obesity and related metabolic conditions has evolved substantially with the emergence of GLP-1 RAs,' they wrote.
'These agents now play a central role not only in weight management and diabetes care but are also being investigated in a growing number of conditions, including cardiovascular, renal, hepatic, neurologic, and substance use disorders.
'As their indications expand, so must our understanding of long-term efficacy, safety, and patient-centred treatment strategies.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
4 hours ago
- Daily Mirror
Weight loss pill that helped patients shift 12% of body mass may soon be on NHS
A weight-loss tablet, which could be a cheaper and easier alternative to jabs and has seen patients during a trial lose up to almost 2st, could soon be available on the NHS A powerful new generation of weight-loss pill that could provide hope for millions of patients is set to be considered by regulators for NHS approval. A trial found overweight people taking the medication lost up to almost 2st – or 12% of their body weight – after 18 months. The maker, US firm Lilly, said it will seek the go-ahead by regulators for the drug orforglipron. It could be a cheaper and easier alternative to weight-loss jabs, which have to be refrigerated. The daily tablet is a GLP-1 agonist, which can cut appetite. Like jabs, the pill mimics the effects of hormones that make us feel full. Lilly also makes weight-loss jab Mounjaro. It comes after the NHS warned mouth symptom could be life-shortening disease. Kenneth Custer, of Lilly, said: 'We're working to transform obesity care with a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments. 'We are planning to submit orforglipron for regulatory review by year-end.' It will need to be approved as safe by the Medicines and Healthcare products Regulatory Agency before the National Institute for Health and Care Excellence decides if it is cost-effective for the NHS. The Mirror understands guidance is expected next year on whether it will be available on the health service. The study found 60% of people on the highest dose of orforglipron lost at least 10% of their body weight. While 40% of people shed at least 15% of their body weight. The study of 3,127 overweight adults also found benefits such as better cholesterol. Lilly said the safety profile of the tablet is similar to other GLP-1 drugs, with gastrointestinal issues the most common side effect. Dr Simon Cork, senior lecturer in physiology at Anglia Ruskin University, said: 'These early results on the effectiveness of orforglipron in promoting clinically significant weight loss are a positive step forward in the development of this class of drugs. 'Their effects on weight loss are not as profound as that seen in [jabs]. 'Nevertheless, that this medication is an oral form, rather than injectable, will likely be seen as more tolerable for many. Manufacturing costs are also anticipated to be significantly lower.' An estimated 1.5 million people in the UK use weight-loss medication, most privately. Mounjaro was due to be rolled out across the NHS in England from June 23 for those with the highest clinical need, but a probe found only eight of 42 NHS integrated care boards are providing it at present. Nearly half of boards say they will cap the number they treat due to lack of funding. NHS England says the plan is for jabs to bemore widely available. Figures suggest about 29% of adults are obese. Another new study has found GLP-1s may have other benefits such as improving Alzheimer's and liver disease.
Western Telegraph
7 hours ago
- Western Telegraph
Mounjaro hair loss searches have more than doubled in a year
Online searches for 'Mounjaro hair loss' have more than doubled in the past year, increasing by 143% . The condition, known as telogen effluvium, is a temporary form of hair loss linked to physical stress. Hair regrowth typically begins three to six months after weight loss stabilises. 'Hair loss on Mounjaro isn't typically due to the medication itself, but rather the metabolic changes that come with sudden weight loss," says Jason Murphy, Head of Pharmacy at Chemist4U. "When people lose a significant amount of weight quickly, typically 10-20% of their body weight in just a few months, it puts the body under stress. "That stress, combined with changes in diet and hormones, can trigger telogen effluvium.' Telogen effluvium causes hair follicles to shift prematurely into their resting phase. Normally, most hair is actively growing, with only a small percentage resting. But when the body is under stress, a larger proportion switches to resting, leading to increased shedding two to three months later. 'This is your body's way of conserving energy during a period of change,' he says. 'Hair growth isn't essential for survival, so the body temporarily redirects energy elsewhere. It's understandably upsetting for patients, but it's actually a protective response.' Recommended reading: How to minimise hair loss during Mounjaro treatment While hair shedding on Mounjaro is often temporary, it can still be distressing for those experiencing it. Fortunately, there are simple, science-backed steps that you can take to protect your hair. 1. Follow proper dose titration "Your doctor or pharmacist will monitor your progress while you're taking Mounjaro," says Jason, an expert in weight loss injections. "Follow your prescribed schedule carefully, this is sometimes called titration, and don't try to increase your dose or lose weight too quickly. Aiming for around 1 to 2 pounds a week is much gentler on the body and can reduce how much hair you shed." 2. Prioritise protein and balanced nutrition Protein is essential for growing healthy hair because it's the building block of new hair cells. It also helps your body produce the enzymes and hormones needed to support hair growth from the inside out. If your diet lacks essential nutrients, a daily multivitamin can help fill the gaps. Look for products with biotin, iron and zinc, as these play an important role in nourishing your hair follicles and scalp. 3. Practice gentle hair care Avoid harsh brushing, heat styling or tight hairstyles like ponytails and braids as these can put extra stress on your hair. Use a mild shampoo that won't strip your scalp of its natural oils. Over-washing can lead to irritation, so washing two to three times a week is often enough unless you have very oily hair. 4. Support scalp health Scalp massage can stimulate blood circulation to the scalp, improving its overall health and promoting hair regrowth. Using a massage brush or your fingertips to massage your scalp can also help distribute haircare products more evenly and make them more effective. If your hair feels dry or damaged, natural remedies like rosemary oil or black tea can help repair it at home. 5. Prioritise sleep and stress management Stress is a well-known trigger for hair loss. To support both your mental health and hair health, build in time for rest, sleep and activities that help you manage stress, whether it's regular exercise, mindfulness or simply taking time out for yourself. Most adults should aim for 7 to 9 hours sleep per night. This is particularly important for those experiencing hair loss, as quality sleep supports the regulation of growth hormone and tissue repair. 6. Explore topical treatments "If you notice hair shedding while taking Mounjaro, speak to your GP or pharmacist about topical Minoxidil (Regaine for Men or Regaine for Women)," says Jason. "Minoxidil encourages blood flow to your scalp and hair follicles. This can help nutrients and oxygen flow into your hair so it grows back stronger."
The Guardian
8 hours ago
- The Guardian
Daily pill helps patients lose 12% of body weight in early trial
A daily weight-loss pill has been shown to help patients lose about 12% of their body weight, according to the results of a clinical trial. The drug, made by the pharmaceutical company Eli Lilly, is a GLP-1 agonist – a type of medication that helps lower blood sugar levels, reduces appetite and slows digestion. More than 3,000 people took part in the 72-week study. Those who received the highest dose – 36mg of orforglipron – lost on average 12.4% of their body weight, compared with just 0.9% of the control group. The trial also showed other health benefits for users, including improvements to cholesterol, blood pressure and heart disease risk. The results come after Novo Nordisk's oral weight loss drug, which has been submitted for approval in the US, helped trial participants lose about 15% of their body weight. Eli Lilly manufactures Mounjaro, a once-a-week injection that contains the drug tirzepatide, which is also used to help improve blood sugar in people with type 2 diabetes. A weight loss pill could offer a more convenient and cheaper alternative – for both patients and the NHS – to injectable treatments that are being rolled out across England. The trial has not yet been peer reviewed and its results are preliminary. Kenneth Custer, the president of Eli Lilly, said: 'With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments. 'With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need.' Dr Simon Cork, a senior lecturer in physiology at Anglia Ruskin University, said although the preliminary results of the effectiveness were a 'positive step forward', they should be interpreted with caution. He said: 'It should be noted that their effects on weight loss are not as profound as that seen in injectable GLP-1 receptor agonists, such as Wegovy, with a lower percentage weight loss and fewer people achieving 10% weight loss at the highest dose. 'It should be noted that these are preliminary, non-peer reviewed results and we will need to see the full trial methodology and data before a more comprehensive analysis can be undertaken.'
